Immunovant, Inc.
Developing FcRn inhibition for multiple autoimmune diseases, with development now focused on IMVT-1402.
Autoimmune disease · FcRn-targeting monoclonal antibody · Registrational Phase 3
Developing FcRn inhibition for multiple autoimmune diseases, with development now focused on IMVT-1402.
Autoimmune disease · FcRn-targeting monoclonal antibody · Registrational Phase 3